A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Clinical trial NCT02284568 · COMPLETED
Trial details
- NCT number
- NCT02284568
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-12
- Primary completion
- 2017-05-04
- Enrollment
- 374
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.